Maraviroc attenuates orbital remodeling, inflammation, and lipid dysregulation in a murine model of thyroid eye disease associated with Graves’ disease [PDF]
Frontiers in EndocrinologyBackgroundGraves’ disease (GD) is an autoimmune condition that can extend beyond the thyroid, leading to thyroid eye disease (TED), a disorder marked by orbital inflammation and tissue remodeling.MethodsWe explored the therapeutic potential of maraviroc,
Fahimeh Hashemi Arani +9 more
doaj +2 more sources
HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. [PDF]
PLoS ONE, 2015 Maraviroc is an HIV entry inhibitor that alters the conformation of CCR5 and is poorly efficient in patients infected by viruses that use CXCR4 as an entry coreceptor.
Christophe Rodriguez +11 more
doaj +3 more sources
Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial. [PDF]
PLoS ONE, 2015 The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore,
Steven F L van Lelyveld +19 more
doaj +3 more sources
Preclinical systematic review of CCR5 antagonists as cerebroprotective and stroke recovery enhancing agents [PDF]
eLifeC-C chemokine receptor type 5 (CCR5) antagonists may improve both acute stroke outcome and long-term recovery. Despite their evaluation in ongoing clinical trials, gaps remain in the evidence supporting their use.
Ayni Sharif +15 more
doaj +2 more sources
Computational investigations of potential inhibitors of monkeypox virus envelope protein E8 through molecular docking and molecular dynamics simulations [PDF]
Scientific ReportsThe World Health Organization (WHO) has declared the monkeypox outbreak a public health emergency, as there is no specific therapeutics for monkeypox virus (MPXV) disease. This study focused on docking various commercial drugs and plant-derived compounds
Rohit Das +3 more
doaj +2 more sources
HIV Research & Clinical Practice, 2022 Background Fostemsavir is an oral prodrug of temsavir, a first‐in‐class attachment inhibitor that binds HIV‐1 gp120, preventing initial HIV attachment and entry into host immune cells.
Mary Beth Wire +4 more
doaj +1 more source
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. [PDF]
PLoS ONE, 2010 Maraviroc treatment for HIV-1 infected patients results in larger CD4(+) T cell rises than are attributable to its antiviral activity alone. We investigated whether this is due to modulation of T cell activation and inflammation.Thirty maraviroc-treated ...
Nicholas Funderburg +8 more
doaj +1 more source
Pharmaceuticals, 2021 Influenza A virus (IAV) infection is a common cause of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Since macrophage inflammatory protein 1 α, a chemokine that acts through CC-chemokine receptor (CCR)-5, appears elevated in COPD
Maximiliano Ruben Ferrero +9 more
doaj +1 more source
Journal of Microbiology and Infectious Diseases, 2023 Background: Tropism is determined by the ability of HIV-1 to bind to the receptors CCR5 or CXCR4 to enter the target cell, which has implications for the pathogenesis of the disease and affects treatment options.
Anamary Suarez Batista +11 more
doaj +1 more source
Clinical Drug Investigation, 2011 Maraviroc belongs to the family of chemokine (C-C motif) receptor 5 (CCR5) antagonists that prevent the entry of human immunodeficiency virus (HIV) into host CD4+ T cells by blocking the CCR5 co-receptor R5. Maraviroc is currently the only CC5R co-receptor inhibitor that has been approved for clinical use in HIV-1-infected patients carrying the CCR5 ...
Parra, Jorge +19 more
+8 more sources